Poseida Therapeutics, Inc. Overview
Pro stress-test →Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics, with a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates. The company creates CAR-T therapies with high levels of TSCM (stem cell-derived memory T cells) for the treatment of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer.
Strategic Profile
Pro stress-test →Poseida's proprietary platforms include the piggyBac non-viral DNA delivery system and the Cas-CLOVER site-specific gene editing system for precise genetic modifications. The company generated $130 million in non-dilutive partnership-related milestones and payments in the first nine months of 2024 and was cash flow positive for that period, with partnerships including Roche and Astellas.
Competitive Landscape
Pro stress-test →Poseida competes in the allogeneic CAR-T and gene therapy market against players like Juno Therapeutics (Celgene/BMS), Caris Life Sciences, and UniQure. The company differentiates through its non-viral piggyBac DNA delivery platform and Cas-CLOVER gene editing system, enabling off-the-shelf, TSCM-rich CAR-T products. Key competitive advantages include rapid patient accessibility without bridging therapy and favorable tolerability profiles in early clinical data.
Industry Context
Poseida Therapeutics, Inc. operates in Allogeneic CAR-T cell therapies and gene editing therapeutics.
Key facts
Founded: 2015 · Headquarters: San Diego, US · Employees: 132 · Revenue: $54.1 million (H1 2024) · Market cap: N/A